Robert Alan Figlin
#119,987
Most Influential Person Now
Robert Alan Figlin's AcademicInfluence.com Rankings
Robert Alan Figlinmedical Degrees
Medical
#1801
World Rank
#2177
Historical Rank
Oncology
#94
World Rank
#98
Historical Rank
Robert Alan Figlinphilosophy Degrees
Philosophy
#5400
World Rank
#8181
Historical Rank
Logic
#2685
World Rank
#3712
Historical Rank
Download Badge
Medical Philosophy
Why Is Robert Alan Figlin Influential?
(Suggest an Edit or Addition)Robert Alan Figlin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (2007) (4385)
- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. (2007) (3560)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009) (2096)
- Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. (2006) (1646)
- Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010) (968)
- Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. (2003) (715)
- Improved prognostication of renal cell carcinoma using an integrated staging system. (2001) (673)
- Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. (2003) (665)
- Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. (2004) (607)
- Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. (2002) (592)
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2011) (570)
- Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. (2009) (474)
- Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. (2000) (459)
- Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. (2006) (450)
- Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. (2005) (366)
- Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. (2004) (360)
- Prognostic relevance of the mTOR pathway in renal cell carcinoma (2007) (357)
- Renal cell carcinoma: prognostic significance of incidentally detected tumors. (2001) (334)
- Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. (2004) (322)
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. (2007) (315)
- An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial (2008) (307)
- Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience (2005) (303)
- Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. (2003) (303)
- Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. (2005) (293)
- Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. (2003) (293)
- NCCN clinical practice guidelines in oncology: kidney cancer. (2009) (286)
- Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. (1997) (282)
- Renal cell carcinoma: management of advanced disease. (1999) (274)
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma (2014) (269)
- Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies (2009) (268)
- Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. (2012) (263)
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (2010) (249)
- S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. (2012) (239)
- Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. (2010) (236)
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. (2012) (234)
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. (2004) (224)
- Akt inhibitors in clinical development for the treatment of cancer (2010) (224)
- Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma (2004) (223)
- Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? (2004) (216)
- A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). (2006) (213)
- Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. (1999) (210)
- Supportive care versus supportive care and combination chemotherapy in metastatic non‐small cell lung cancer. Does chemotherapy make a difference? (1989) (204)
- Novel approaches in the therapy of metastatic renal cell carcinoma (2005) (202)
- Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. (2008) (197)
- Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma (2008) (195)
- Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. (2017) (194)
- Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. (2003) (194)
- Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. (2004) (193)
- Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the functional living index—cancer (1988) (193)
- Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. (2003) (191)
- Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. (2003) (187)
- Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) (2008) (187)
- A molecular classification of papillary renal cell carcinoma. (2005) (186)
- Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma (2003) (184)
- Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. (1999) (182)
- Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. (2005) (178)
- Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis (2012) (176)
- NCCN clinical practice guidelines in oncology: testicular cancer. (2009) (173)
- Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer (2003) (170)
- Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma (2005) (163)
- The treatment of renal cell carcinoma with human leukocyte alpha-interferon. (1983) (162)
- Targeted therapies for renal cell carcinoma (2017) (161)
- Surveillance strategies for renal cell carcinoma patients following nephrectomy. (2006) (161)
- The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) (2019) (158)
- Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. (2000) (157)
- Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results (2015) (155)
- Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. (1997) (153)
- Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. (2001) (150)
- Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. (1993) (146)
- Renal cell carcinoma with retroperitoneal lymph nodes (2003) (145)
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. (2011) (143)
- Monitoring cancer treatment with PET/CT: does it make a difference? (2007) (143)
- The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma1 (2005) (139)
- TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. (2003) (139)
- Collecting duct renal cell carcinoma: clinical study of a rare tumor. (2002) (135)
- Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) (2006) (135)
- Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. (1995) (130)
- Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. (2010) (128)
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma (2014) (127)
- Epithelial Cell Adhesion Molecule (KSA) Expression (2004) (127)
- Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer (1999) (126)
- Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. (2003) (124)
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. (2012) (123)
- Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. (1991) (122)
- Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. (2001) (121)
- Bullous pyoderma gangrenosum after granulocyte colony‐stimulating factor treatment (1991) (119)
- Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. (1988) (118)
- Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. (1992) (116)
- Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies (2008) (115)
- Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma (2007) (114)
- Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. (2011) (113)
- Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. (2005) (113)
- Surveillance following radical or partial nephrectomy for renal cell carcinoma (2005) (112)
- STAT3: a target to enhance antitumor immune response. (2011) (112)
- Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. (2010) (110)
- A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung Cancer (2006) (108)
- Mathematical model to predict individual survival for patients with renal cell carcinoma. (2002) (107)
- Renal cell carcinoma: recent progress and future directions. (1997) (105)
- Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. (2003) (101)
- Wearable activity monitors in oncology trials: Current use of an emerging technology. (2018) (100)
- Adoptive cellular therapy. (2000) (100)
- Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. (2001) (99)
- Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High‐grade non‐Hodgkin's lymphoma and chronic lymphocytic leukemia (1999) (97)
- p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. (2005) (97)
- Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. (2001) (97)
- The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). (2010) (96)
- Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. (1999) (95)
- Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. (2009) (94)
- A Pilot Trial of Tumor Lysate-Loaded Dendritic Cells for the Treatment of Metastatic Renal Cell Carcinoma (2003) (94)
- The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. (2002) (92)
- Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors (2007) (92)
- 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib (2011) (90)
- Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients (2018) (90)
- Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α (2009) (88)
- Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor (2008) (88)
- Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. (2007) (87)
- Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape (2010) (85)
- A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma (2003) (83)
- Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). (2006) (83)
- Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. (2003) (82)
- Prognostic factors and selection for clinical studies of patients with kidney cancer. (2008) (82)
- Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). (2006) (82)
- Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT) (2007) (82)
- SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. (2004) (79)
- Interferon in renal cell carcinoma. The UCLA experience (1987) (79)
- HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma (2019) (78)
- Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors (2013) (77)
- Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. (1997) (77)
- A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. (2003) (75)
- Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma (2007) (74)
- Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. (2002) (74)
- Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. (2004) (73)
- Cystic renal cell carcinoma: biology and clinical behavior. (2004) (73)
- Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. (1999) (72)
- Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients With Advanced Prostate Cancer (2004) (71)
- Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (2014) (71)
- In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. (1996) (70)
- Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. (1996) (70)
- p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. (2007) (69)
- Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma (2007) (68)
- Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? (2002) (68)
- Frequent amplification of the bcl-1 locus in poorly differentiated squamous cell carcinoma of the lung. The Lung Cancer Study Group. (1990) (67)
- Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma (2009) (67)
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma (2016) (66)
- Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. (1988) (65)
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma (2014) (65)
- Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. (2007) (63)
- A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models (2013) (63)
- Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. (1996) (62)
- Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. (2003) (62)
- Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial. (1985) (61)
- Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. (2004) (61)
- Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. (2000) (61)
- Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. (2004) (61)
- Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework. (2017) (60)
- Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. (1996) (60)
- Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. (2009) (60)
- Treatment of patients with metastatic renal cell cancer (2006) (59)
- Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. (2017) (59)
- Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. (2001) (58)
- Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma (1993) (58)
- An association between renal cell carcinoma and lymphoid malignancies: A case series of eight patients (1996) (56)
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy (2007) (56)
- Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma (2013) (56)
- Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-Cadherin (2008) (56)
- Current management of renal cell carcinoma (1996) (55)
- Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. (2003) (55)
- Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies (2005) (54)
- Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma (2005) (54)
- Sequential use of targeted agents in the treatment of renal cell carcinoma. (2011) (54)
- Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial (2008) (52)
- Quantitative Polymerase Chain Reaction Does not Improve Preoperative Prostate Cancer Staging: A Clinicopathological Molecular Analysis of 121 Patients (1998) (52)
- COVID-19 and androgen targeted therapy for prostate cancer patients. (2020) (52)
- NCCN Task Force Report: mTOR inhibition in solid tumors. (2008) (52)
- Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy? (2007) (52)
- Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma (2010) (51)
- Validation of the ucla integrated staging system for patients with renal cell carcinoma. (2001) (50)
- Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. (2006) (50)
- Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861. (1994) (49)
- Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer (1998) (49)
- Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy (2004) (48)
- The role of targeting mammalian target of rapamycin in lung cancer. (2008) (48)
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC) (2007) (47)
- Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. (1995) (47)
- Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma (2002) (47)
- Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The ucla experience (1995) (46)
- Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer? (2012) (46)
- Systemic therapy in renal cell carcinoma: advancing paradigms. (2012) (46)
- G250: A carbonic anhydrase IX monoclonal antibody (2005) (45)
- Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. (2011) (45)
- Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials (2007) (43)
- Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program (2010) (43)
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy (2012) (42)
- CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer (2009) (42)
- Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma (2011) (42)
- Current staging of renal cell carcinoma. (2003) (40)
- Green Tea Extract Modulates Actin Remodeling via Rho Activity in an In vitro Multistep Carcinogenic Model (2005) (40)
- Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference (2007) (39)
- Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. (2004) (39)
- Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group. (2008) (39)
- Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma (2008) (39)
- Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex (2000) (38)
- Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group (2018) (38)
- TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). (2010) (37)
- A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. (2006) (37)
- Pulmonary toxicity of recombinant human tumor necrosis factor. (1989) (37)
- Advances in immune-based therapies of renal cell carcinoma (2004) (37)
- A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stage II and III non-small cell carcinoma of the lung. (1994) (37)
- Annexin‐I as a potential target for green tea extract induced actin remodeling (2007) (36)
- Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. (2000) (36)
- Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. (1995) (35)
- Cytokine-based therapy for metastatic renal cell cancer. (2003) (35)
- In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin‐2 and/or interferon‐alpha gene transfer (1994) (35)
- Evolving role of novel targeted agents in renal cell carcinoma. (2007) (35)
- Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. (2014) (35)
- Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance (2018) (35)
- Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer (2015) (34)
- Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy (2007) (33)
- Renal cell carcinoma: basic biology and current approaches to therapy. (1991) (33)
- Renal Cell Cancer (2007) (32)
- Overexpression of CCL-21/Secondary Lymphoid Tissue Chemokine in Human Dendritic Cells Augments Chemotactic Activities for Lymphocytes and Antigen Presenting Cells (2003) (32)
- Measuring the incremental cost of clinical cancer research. (2001) (32)
- Heterogeneity of Patients With Intermediate‐Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib (2017) (32)
- Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors (1993) (32)
- Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma (2005) (32)
- Genitourinary tumors, non-prostate (2012) (31)
- Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC). (2006) (31)
- The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma. (1991) (31)
- Generation of Kidney Cancer-Specific Antitumor Immune Responses Using Peripheral Blood Monocytes Transduced With a Recombinant Adenovirus Encoding Carbonic Anhydrase 9 (2004) (30)
- Prognostic factors in renal cell carcinoma. (2006) (30)
- Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options (2005) (29)
- Novel agents and approaches for advanced renal cell carcinoma. (2012) (29)
- Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. (1997) (29)
- Granulocyte/macrophage‐colony stimulating factor and interleukin‐4 expand and activate type‐1 dendritic cells (DC1) when administered in vivo to cancer patients (2003) (28)
- Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma (2020) (28)
- Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma (2005) (28)
- Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. (1996) (28)
- Innovations and Challenges in Renal Cancer (2004) (28)
- Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α (2012) (28)
- Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. (2019) (28)
- Temsirolimus for advanced renal cell carcinoma. (2007) (27)
- Targeted therapy for sarcomas (2014) (27)
- Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. (2011) (27)
- Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. (1997) (27)
- Integrated multimedia timeline of medical images and data for thoracic oncology patients. (1996) (27)
- Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC) (2007) (27)
- Novel therapeutics for metastatic renal cell carcinoma (2009) (26)
- Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers (2010) (26)
- Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). (2013) (26)
- Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway (2005) (25)
- Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis. (2013) (24)
- Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. (2006) (24)
- Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: A tissue array based analysis (2005) (24)
- Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America (2008) (24)
- Atypical contrast reactions associated with systemic interleukin-2 therapy. (1991) (24)
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis (2012) (24)
- A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma (2017) (24)
- Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. (1983) (24)
- Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum. (1983) (24)
- A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. (1998) (24)
- Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC (2008) (23)
- Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma (2005) (23)
- The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma. (1995) (23)
- Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis (2006) (23)
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM) (2007) (23)
- A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome (2017) (22)
- Chemokines as therapeutic targets in renal cell carcinoma (2008) (22)
- Phase I study of recombinant beta ser 17 interferon in the treatment of cancer. (1986) (22)
- Immunotherapy and gene therapy. (1996) (22)
- A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. (2017) (22)
- The biology of the cytokine sequence cascade. (1996) (22)
- Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? (2016) (22)
- Targeted therapies for renal cell carcinoma: understanding their impact on survival (2010) (21)
- A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. (2010) (21)
- A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects. (1990) (21)
- Adjuvant treatment for renal cell carcinoma (2006) (21)
- Infusional interleukin‐2 and 5‐fluorouracil with subcutaneous interferon‐α for the treatment of patients with advanced renal cell carcinoma (2000) (21)
- ADAPT: An ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC). (2014) (21)
- Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. (2001) (21)
- Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. (1994) (21)
- The role of molecular markers in the staging of renal cell carcinoma (2007) (21)
- Diabetes Mellitus in Cancer Patients Treated with Combination Interleukin 2 and α-Interferon (1995) (21)
- Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? (2018) (20)
- Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma. (1989) (20)
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment (2007) (20)
- Vaccine and gene therapy of renal cell carcinoma. (2001) (20)
- Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. (1990) (20)
- Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma (2014) (19)
- Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference (2009) (19)
- A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (2011) (19)
- Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma (2015) (19)
- 257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2009) (18)
- Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma (2011) (18)
- Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). (2009) (18)
- Literature Review and Profile of Cancer Diseases Among Afghan Refugees in Iran: Referrals in Six Years of Displacement (2015) (18)
- Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions. (2014) (17)
- Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. (2000) (17)
- A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma (2000) (17)
- Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. (1993) (17)
- Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer (2015) (17)
- Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. (2011) (17)
- Practice guidelines for non-small cell lung cancer. (1996) (17)
- Renal and adrenal tumors : biology and management (2002) (17)
- CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic (2021) (17)
- Renal cell carcinoma: basic biology and clinical behavior. (1996) (17)
- Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma (2003) (16)
- Myeloid Clusters Are Associated with a Pro-Metastatic Environment and Poor Prognosis in Smoking-Related Early Stage Non-Small Cell Lung Cancer (2013) (16)
- Long‐Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials (2017) (16)
- Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. (1993) (16)
- A new age for vaccine therapy in renal cell carcinoma. (2013) (16)
- Dendritic cell-based immunotherapy of renal cell carcinoma (2001) (16)
- Management of disseminated kidney cancer. (1994) (16)
- Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. (2002) (15)
- Adenovirus‐Mediated Interleukin‐2 Production by Tumors Induces Growth of Cytotoxic Tumor‐Infiltrating Lymphocytes Against Human Renal Cell Carcinoma (1998) (15)
- Phase I Trial of Granulocyte Macrophage-Colony Stimulating Factor and Interleukin-4 as a Combined Immunotherapy for Patients With Cancer (2003) (15)
- Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). (2012) (15)
- 4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors (2007) (14)
- Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults (2011) (14)
- Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. (2019) (14)
- A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). (2009) (14)
- Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma (2019) (14)
- Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough? (2016) (14)
- Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results. (1989) (14)
- Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma. (2013) (14)
- Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma (2008) (14)
- 1139 POSTER Asthenia and Fatigue as Potential Biomarkers of Sunitinib Efficacy in Metastatic Renal Cell Carcinoma (2011) (13)
- Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection. (1991) (13)
- Practice guidelines for breast cancer. (1996) (13)
- Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors (2010) (13)
- 996: Prognostic Significance of T3A Renal Cell Carcinoma with Adrenal Gland Involvement: An International Multicenter Experience (2005) (13)
- RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. (2006) (13)
- A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC)-a preliminary report (2004) (13)
- Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. (2019) (13)
- Renal cell carcinoma therapy in 2010: many options with little comparative data. (2010) (13)
- Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy. (1993) (13)
- Tivozanib: current status and future directions in the treatment of solid tumors (2012) (12)
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts) (2007) (12)
- Biotherapy with interferon--1988. (1988) (12)
- 300 A COMPARISON OF KU0063794, A DUAL MTORC1 AND MTORC2 INHIBITOR, AND TEMSIROLIMUS IN PRECLINICAL RENAL CELL CARCINOMA MODELS (2012) (12)
- Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma (2017) (12)
- Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer (2019) (11)
- Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study (2007) (11)
- Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (2004) (11)
- Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model (2006) (10)
- Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials (2016) (10)
- Renal cell carcinoma: An update for the practicing urologist (2015) (10)
- Myocarditis temporally related to the use of gefitinib (Iressa). (2005) (10)
- The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. (2016) (10)
- Immunotherapy in Renal Cell Carcinoma; Cellular Immunotherapy (1996) (10)
- Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanoma. (1987) (10)
- Targeting angiogenesis in renal cell carcinoma (2013) (10)
- Anti-interferon antibodies: a perspective. (1988) (10)
- Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. (2022) (10)
- Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC). (2014) (10)
- Effect of in vivo administration of interferon on human monocyte function. (1983) (9)
- A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). (2010) (9)
- Kidney cancer: Progress and controversies in neoadjuvant therapy (2014) (9)
- 1137OInterim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC) (2017) (9)
- A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma (2005) (9)
- Phase I study of Wellferon (human lymphoblastoid alpha-interferon) as cancer therapy: clinical results. (1983) (9)
- Immune gene therapy for kidney cancer: the search for a magic trigger. (2003) (9)
- Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC). (2004) (9)
- Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer. (2019) (9)
- Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study. (2011) (9)
- Practice guidelines for pancreatic cancer. (1996) (9)
- Tumor necrosis factor: current clinical status and implications for nursing management. (1988) (8)
- EFFECT OF INTERLEUKIN-2 (IL-2) GENE THERAPY ON PROSTATE SPECIFIC ANTIGEN IN PATIENTS UNDERGOING NEOADJUVANT OR ADJUVANT GENE THERAPY FOR PROSTATE CANCER (1999) (8)
- Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer (2016) (8)
- Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape (2010) (8)
- Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). (2012) (8)
- Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. (2008) (8)
- Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection (2021) (8)
- Diabetes mellitus in cancer patients treated with combination interleukin 2 and alpha-interferon. (1995) (8)
- A phase I trial of targeted COX-2 and EGFR TK inhibition in advanced NSCLC (2005) (8)
- Commentary on Prognostic Factors in Renal Cell Carcinoma (1995) (8)
- Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial (2017) (7)
- Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer. (1985) (7)
- Induction of G 250-targeted and T-Cell-mediated Antitumor Activity against Renal Cell Carcinoma Using a Chimeric Fusion Protein Consisting of G 250 and Granulocyte / Monocyte-Colony Stimulating Factor (2001) (7)
- The Stromal Derived Factor‐1/CXCL12‐CXC Chemokine Receptor 4 Biological Axis in Renal Cell Carcinoma Metastasis (2006) (7)
- Recombinant human interleukin 4 (IL-4) sch 39400 in non-small cell lung cancer (NSCLC): Results of a phase II investigation (1994) (7)
- Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma (2019) (7)
- Circulating tumor cells in prostate cancer: beyond enumeration. (2017) (7)
- Practice guidelines for esophageal cancer. (1996) (7)
- 246 OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) (2009) (7)
- Optimal dosing of ABX-EGF in cancer patients (2002) (7)
- Practice guidelines for colorectal cancer. (1996) (7)
- Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL‐6, and IL‐8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib (2009) (6)
- Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment? (2020) (6)
- Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment. (2004) (6)
- 740: Can PT2 Classification for Renal Cell Carcinoma be Improved? an International Multicenter Experience? (2006) (6)
- Renal cell carcinoma: current status and future plans. (2000) (6)
- The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombina (1992) (6)
- CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma. (2019) (6)
- The value of surrogate endpoints for predicting real-world survival across five cancer types (2016) (6)
- Experimental therapy for advanced renal cell carcinoma. (2008) (6)
- Multi-Epitope CTL Responses Induced by a Peptide Vaccine (EP-2101) in Colon and Non-Small Cell Lung Cancer Patients (2004) (6)
- Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib. (2014) (6)
- Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). (2005) (6)
- Correlating wearable activity monitor data with PROMIS detected distress and physical functioning in advanced cancer patients. (2017) (6)
- A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. (2004) (6)
- Consistency of a two clinical site sample collection: A proteomics study (2010) (6)
- A Phase I Trial of CD 3 / CD 28-activated T Cells ( Xcellerated T Cells ) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma 1 (2003) (6)
- Bevacizumab plus interferon α in patients with metastatic renal cell carcinoma (2008) (6)
- Understanding the role of MET kinase in cancer therapy. (2013) (6)
- COST EFFECTIVENESS OF FDG WHOLE BODY PET IN THE EVALUATION OF RENAL CELL CA (1995) (5)
- A Multicenter, Randomized, Phase 3 Trial of a Novel Autologous Therapeutic Vaccine (Vitespen) Vs. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence After Nephrec- tomy for Renal Cell Carcinoma (2006) (5)
- Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma: A phase II study of the Southwest Oncology Group (1996) (5)
- Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics. (2021) (5)
- 1651: Molecular Prognostic Modeling Using Protein Expression Profile in Clear Cell Renal Carcinoma (2004) (5)
- Practice guidelines for gastric cancer. (1996) (5)
- Assessing performance status and clinical outcomes with wearable activity monitors. (2017) (5)
- Biotherapy in clinical practice. (1989) (5)
- 860 PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE VERSUS INTERFERON-ALFA AS FIRST-LINE SYSTEMIC THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2007) (5)
- Deciphering the anticancer mechanisms of sunitinib (2010) (5)
- SORAFENIB THERAPY IN THE MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA WITH BRAIN METASTASES: RESULTS FROM THE ARCCS EXPANDED ACCESS PROGRAM (2008) (5)
- Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC) (2004) (5)
- Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous. (2019) (5)
- A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. (2016) (5)
- Use of carbonic anhydrase IX (CAIX) expression and Von Hippel Lindau (VHL) gene mutation status to predict survival in renal cell carcinoma (2007) (4)
- A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. (2014) (4)
- Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma. (1999) (4)
- A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy (2016) (4)
- Combined cytoreductive laser therapy and immunotherapy for palliation of metastatic renal cell carcinoma to the head and neck (2007) (4)
- Circulating protein biomarkers of sunitinib (SU) and interferon-α (IFN-α) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC). (2011) (4)
- Experimental therapy for advanced renal cell carcinoma (2008) (4)
- Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. (2011) (4)
- Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. (2020) (4)
- Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer. (2012) (4)
- 350: Characterization of the MTOR Pathway in Renal Cell Carcinoma and its Use in Predicting Patient Selection for Agents Targeting this Pathway (2005) (4)
- SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS FROM A PHASE III RANDOMISED TRIAL (2008) (4)
- Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer (2020) (4)
- Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial. (2018) (4)
- Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC). (2015) (4)
- MULTI-ANTIGEN LOADED DENDRITIC CELL (DC) VACCINE FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (mRCC)-IN-VITRO CORRELATES (1999) (4)
- Immunotherapy for renal cell carcinoma. (1992) (4)
- Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach (2009) (4)
- Randomized, placebo-controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-small cell lung cancer. (2010) (3)
- 718: The P21 Growth and Apoptosis Regulatory Protein is an Independent Predictor of Survival in Patients with Clear Cell Renal Cell Carcinoma (2006) (3)
- Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States. (2016) (3)
- 858 SAFETY ANALYSIS OF THE ADVANCED RENAL CELL CARCINOMA SORAFENIB (ARCCS) STUDY, AN EXPANDED ACCESS PROGRAM (2007) (3)
- Kaposi's sarcoma and immunoblastic sarcoma in the acquired immune deficiency syndrome. (1984) (3)
- Human α‐lymphoblastoid interferon: A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU‐GMs) (1985) (3)
- Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma (2004) (3)
- Primary tumors of the lung other than lung cancer (1993) (3)
- Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights. (2017) (3)
- Pazopanib in the treatment of renal cell carcinoma (2011) (3)
- Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference (2004) (3)
- Practice guidelines for small cell lung cancer. (1996) (3)
- 281 Safety and efficacy of partial nephrectomy for all T1 tumours based on an international multicentre experience (2004) (3)
- Cellular therapy of renal cell carcinoma past, present, future (1997) (3)
- Talactoferrin alfa may prolong progression-free survival in advanced renal carcinoma patients. (2006) (3)
- O-287 Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory of resistant non-small cell lung cancer (NSCLC) (2003) (3)
- Immunotherapy for metastatic renal-cell carcinoma (1991) (3)
- Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview (2009) (3)
- 741: Microvascular Invasion is Associated with Aggressive Clinicopathological Features and is an Independent Predictor of Survival for Patients with Clear Cell Renal Cell Carcinoma (2006) (3)
- A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes. (2014) (2)
- 3036 POSTER Comparison of Health-related Quality of Life (HRQoL) In Patients Reporting the Same Adverse Event (AE) Fatigue on Different Treatments (2011) (2)
- 723: Significance of Tumor Size in Locally Advanced Renal Cell Carcinoma (PT3A): An International Multicenter Experience (2006) (2)
- Cell, gene and vaccine based strategies in kidney cancer. (2003) (2)
- Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction (2015) (2)
- Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT* phase 3 study experience. (2014) (2)
- 719 EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF PATIENTS WITH A REDUCTION IN TUMOR BURDEN ENROLLED IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE II TRIAL (2011) (2)
- 1757: The Prognostic Value of Histologic Subtypes in Renal cell Carcinoma (RCC). A Multicenter Experience in 4063 Patients (2004) (2)
- The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. (2016) (2)
- Pathologic response and long term results of preoperative M-VAC regimen in regionally advanced transitional cell carcinoma of the bladder. (1993) (2)
- First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been? (2022) (2)
- Applications of wearable activity monitors (WAM) in cancer clinical trials (CT): A review of the literature. (2016) (2)
- 4520 POSTER Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study (2007) (2)
- Abstract LB-260: Combination of Foxp3+ T cells depletion and mTOR inhibitor enhances immune memory and controls cancer growth (2014) (2)
- The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma (2005) (2)
- 621: Molecular Tumor Grading of Clear Cell Renal Cell Carcinoma Using Protein Expression of the Vascular Endothelial Growth Factor (VEGF) Family (2005) (2)
- MD and RN ECOG-PS assessments prior to chemotherapy and concordance rates: A quality initiative at a comprehensive cancer center. (2016) (2)
- Immunologic approaches to the treatment of cancer. (1995) (2)
- Clinical outcome and molecular characterization of patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma. (2012) (2)
- Practice guidelines for prostate cancer. (1996) (2)
- From the guest editor: renal cell carcinoma: the next decade of development. (2013) (2)
- 216: Low CAIX Expression and Absence of VHL Gene Mutation are Associated with Tumor Aggressiveness and Poor Survival in Patients with Renal Cell Carcinoma (RCC) (2007) (2)
- What are the indications for sorafenib treatment in patients with renal cell carcinoma? (2007) (2)
- Unraveling the role of hypoxia-inducible factor in renal cell carcinoma: a biological and therapeutic perspective. (2011) (2)
- Ramucirumab in metastatic renal cell carcinoma: The beginning or the end? (2014) (2)
- Accelerating the clinical trial start-up process for early-phase cancer studies: A test of process change to support rapid activation in an academic medical center. (2013) (2)
- Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC). (2004) (1)
- Patient identification and eligibility insights in the synchronous metastatic RCC population: An update from the ongoing ADAPT* phase 3 study experience. (2015) (1)
- Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially. (2009) (1)
- 1574PA TRANSLATIONAL PHASE 2 STUDY OF CABOZANTINIB IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WITH VISCERAL METASTASES WITH CHARACTERIZATION OF CIRCULATING TUMOR CELLS AND LARGE ONCOSOMES. (2014) (1)
- Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials (2012) (1)
- Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules (2010) (1)
- Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care. (2018) (1)
- Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2011) (1)
- Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer. (2021) (1)
- Cancer immunotherapy using tumor-infiltrating lymphocytes. (1992) (1)
- Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. (2023) (1)
- Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma (2004) (1)
- AGGRESSIVE SURGICAL RESECTION COMBINED WITH LOW-DOSE RIL 2-BASED ADOPTIVE IMMUNOTHERAPY FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC); SURGICAL BIOLOGY OF A LARGE MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED PHASE II/III STUDY (1999) (1)
- VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition (2009) (1)
- 91: Comparison Between Open and Laparoscopic Nephron Sparing Surgery. Results From a Multicenter Experience (2006) (1)
- Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-alpha 2a (rIFN-alpha 2a). (1988) (1)
- Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group. (2017) (1)
- A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC)-a preliminary report. (2004) (1)
- Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC). (2011) (1)
- The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM (2009) (1)
- 1331: Expression of Vascular Endothelial Growth Factor A (VEGF-A), VEGF Receptor 1 (VEGFR-1) and VEGFR-2 in Clear Cell and Papillary Renal Cell Carcinoma (RCC): Implications for Therapy (2005) (1)
- LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. (2023) (1)
- Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC). (2016) (1)
- 65 POSTER Safety of Volociximab as a monotherapy and in combination with chemotherapy the result of three phase II studies (2006) (1)
- 372: Expression Analysis of the Vascular Endothelial Growth Factor (VEGF) Family in Renal Cell Carcinoma: Targeting the VEGF Pathway (2006) (1)
- Utilizing Eastern Cooperative Oncology Group (ECOG) performance status scores to prevent harm with chemotherapy at the end of life. (2014) (1)
- A phase II trial assessing pazopanib (paz) as third-line therapy for metastatic renal cell carcinoma (mRCC): Clinical outcome and temporal analysis of molecular profile. (2013) (1)
- O-194 Targeted COX-2 and EGFR inhibition in advanced NSCLC (2005) (1)
- Use of VEGFR1 expression in benign pelvic lymph nodes to predict biochemical recurrence in patients with high-risk prostate cancer. (2012) (1)
- A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies. (2016) (1)
- Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis. (2006) (1)
- Newly approved therapies for RCC and their effect on the standard of care. (2007) (1)
- Third-Line Treatment Options for Kidney Cancer. (2016) (1)
- Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium. (2018) (1)
- PCN200 Using A Weibull Parametric Model for Failure-Time Data to Assess Progression-Free Survival as A Surrogate Endpoint for Overall Survival in A Trial of Patients with Metastatic Renal Cell Carcinoma (2011) (1)
- Novel Circulating Proteins, Single Nucleotide Polymorphisms (SNPS), and Molecular Tumor Markers as Potential Biomarkers of Sunitinib Efficacy in Treatment-Naïve Patients (PTS) with Advanced Renal Cell Carcinoma (RCC) (2012) (1)
- 1447O Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003 (2022) (1)
- Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies (2012) (1)
- IMMUNOTHERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCCa) USING INTERLEUKIN-2 (IL-2) BASED THERAPY ADMINISTERED EITHER ALONE OR WITH IN VIVO PRIMED OR CD8+ SELECTED TUMOR INFILTRATING LYMPHOCYTES (TIL): THE UCLA EXPERIENCE (1993) (1)
- Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-α2a (rIFN-α2a) (1988) (1)
- 259 Phase II trial of recombinant interleukin-4 (IL-4 SCH 39400) in advanced non-small cell lung cancer (NSCLC); a dose ranging study (1997) (0)
- Changes, Challenges and Opportunities in Cancer Care During the COVID-19 Era and Beyond: Building on Lessons Learned From the Pandemic (2021) (0)
- Updated immunologic and clinical results from a phase 2 study of AGS-003, an autologous dendritic cell based therapy, in patients with newly diagnosed metastatic renal cell carcinoma in combination with sunitinib. (2011) (0)
- The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma (2021) (0)
- Characterizing Complete Responders to IL-2 Using Gene Expression Analysis and Tissue Array Validation in Patients with Metastatic Renal Cell Carcinoma (2004) (0)
- UROLOGICAL ONCOLOGY: RENAL, URETERAL AND RETROPERITONEAL TUMORS (2008) (0)
- Local response and long-term results of preoperative M-VAC regimen in regionally advanced transitional cell carcinoma of the bladder. (1993) (0)
- This Month in Investigative Urology COMMENTARY ON PROGNOSTIC FACTORS IN RXNAL CELL CARCINOMA (1995) (0)
- Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma (2022) (0)
- Specific immunotherapy of MUC1-positive adenocarcinomas with a recombinant vaccinia virus expressing MUC1 and IL-2 (2001) (0)
- Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. (2022) (0)
- MODULATION OF THE CYCLOOXYGENASE PATHWAY IS ASSOCIATED WITH EFFICACY IN A RANDOMIZED PHASE II TRIAL OF ERLOTINIB AND CELECOXIB OR PLACEBO IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) (2013) (0)
- Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy1 (2004) (0)
- 636: Hematogenous Versus Lymphatic Dissemination: The Role of the Vascular Endothelial Growth Factor (VEGF) Family in the Metastatic Process of Clear Cell Renal Cell Carcinoma (2005) (0)
- Renal cell carcinoma and interleukin-2: what are the endpoints? (1997) (0)
- Renal Cell Carcinoma : Recent Progress and Future Directions 1 (2017) (0)
- 1750: Prognostic Impact of Chromosomal Alterations in Renal cell Carcinoma Following Surgical Resection (2004) (0)
- Faculty Opinions recommendation of Sunitinib in patients with metastatic renal cell carcinoma. (2006) (0)
- From the Guest Editor: Renal Cell Carcinoma (2013) (0)
- Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma (2022) (0)
- Abstract LB-275: 5-miRNA signature to predict clear cell renal cell carcinoma metastasis and prognosis (2010) (0)
- TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH CD8( +) SELECTED TUMOR INFILTRATING LYMPHOCYTES FROM PRIMARY TUMOR NEPHRECTOMY, INTERLEUKIN-2 AND CYTOKINE-PRIMED OR (1997) (0)
- CYTOKINE (CK) RELEASE PATTERN UPON AUTOLOGOUS TUMOR STIMULATION OF RENAL TUMOR-INFILTRATING LYMPHOCYTES (TIL): EVIDENCE FOR HIGHER SPECIFIC KILLING BY TNFSECRETORS IN VITRO (1993) (0)
- Advance Care Planning in Patients With Metastatic Cancer: A Quality Improvement Initiative (2022) (0)
- Sunitinib tolerance following an initial exposure period: Results of longitudinal PRO data from S-TRAC study. (2018) (0)
- How well do surrogate endpoints and overall survival endpoints in clinical trials predict real-world survival? (2015) (0)
- 1099: Prognostic Factors and Long-Term Outcome Following Resection of Renal Cell Carcinoma with Right Atrial Extension: Impact on Survival and Benefits of Immunotherapy (2006) (0)
- 1656: The Use of Uiss (Ucla Integrated Staging System) to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study in 4202 Patients (2004) (0)
- Abstract 407: Detection of phospho-Stat3-mediated immunosuppressive microenvironment in benign lymph nodes of patients with early stage non-small cell lung cancer (2011) (0)
- Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis (2009) (0)
- Contributors (2019) (0)
- 680Hematogenous versus lymphatic dissemination: The role of the vascular endothelial growth factor (VEGF) family in the metastatic process of clear cell renal cell carcinoma (2005) (0)
- Treatment of metastatic kidney cancer (2010) (0)
- Renal cell carcinoma: the translation of biology to clinical application. (2006) (0)
- 51: Morbidity and Clinical Outome of Nephron Sparing Surgery in Relation to Tumor Size and Indication (2006) (0)
- CCR Drug Updates Cabazitaxel : More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer ? (2012) (0)
- Advances in adjuvant therapies for renal cell carcinoma (2005) (0)
- Abstract CT334: Pazopanib as third-line therapy for metastatic renal cell carcinoma: Clinical efficacy and temporal analysis of cytokine profile (2014) (0)
- The Social Value of Immunotherapy in Non-Small Cell Lung Cancer (2016) (0)
- 2572 Clinical and translational assessment of VEGFR1 as a mediator of the pre-metastatic niche: Neoadjuvant axitinib in high-risk localized prostate cancer (2015) (0)
- Application of a new method for detecting the phenotype of target binding cells (2004) (0)
- Introduction by the Guest Editor: Challenges and Opportunities for the Next Era of Development in Kidney Cancer. (2020) (0)
- Improving the efficiency and effectiveness of clinical research regulatory review processes: Lessons from the Six Sigma Body of Knowledge. (2009) (0)
- Microenvironment and Immunology Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD 1480 (2011) (0)
- Non-small cell lung cancer. (2008) (0)
- Long-term survivorship for patients with non-small cell lung cancer (NSCLC) treated with nivolumab (nivo): a response-based modeling approach (2017) (0)
- Digitally captured step counts for evaluating performance status in advanced cancer patients: A single cohort, prospective trial (Digi-STEPS). (2019) (0)
- 1212 Improvements in progression-free survival and real-world cost: A study of treatments for five tumor sites (2015) (0)
- Abstract 405: The role of Stat3 in pre-metastatic niche formation: Examination in murine models and benign lymph nodes from prostate cancer patients (2011) (0)
- 1332: Complete Reponse to Immunotherapy in Metastatic Renal Cell Carcinoma: Gene Expression and Tissue Microarray Analysis (2005) (0)
- Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum] (2021) (0)
- 738: Pilot Study to Determine the Incidence of Circulating Renal Cell Carcinoma (RCC) Cells in Patients with Metastatic Disease Before and after Treatment with IL-2 Therapy (2006) (0)
- Comparing physician and nurse ECOG performance status ratings as predictors of clinical outcomes in cancer patients. (2017) (0)
- Immunotherapy and Chemotherapy for Metastatic Renal Cell Carcinoma (1999) (0)
- 782: Identification of T Cell Clones that Recognize Shared Renal Cell Carcinoma Antigens (2004) (0)
- Use of VEGFR1 expression in benign pelvic lymph nodes to predict biochemical recurrence in patients with high-risk prostate cancer. (2012) (0)
- Tivozanib in renal cell carcinoma. (2013) (0)
- Carbonic Anhydrase IX: Biology and Clinical Approaches (2009) (0)
- O-150 A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with advanced stage or metastatic non-small cell lung cancer (NSCLC) (2003) (0)
- POETRY BY CANCER CAREGIVERS (2007) (0)
- Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy. (2016) (0)
- Molecularly Targeted Staging Strategies in Renal Cell Carcinoma (2015) (0)
- Targeted COX-2 and EGFR TK inhibition in advanced non-small cell lung cancer. (2006) (0)
- 645: Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3) is Highly Expressed in the Tumor Endothelium of Clear Cell but not Papillary Renal Cell Carcinoma (RCC): Implications for Therapy (2005) (0)
- QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC) (2022) (0)
- A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome (2017) (0)
- Granulocyte Macrophage Colony-stimulating Factor and Interleukin 4 Enhance the Number and Antigen-presenting Activity of Circulating CD 14 1 and CD 83 1 Cells in Cancer Patients 1 (2000) (0)
- MA14.09 Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies (2017) (0)
- Compositions for the increase in the number of antigen-presenting cells and the anti-tumor response in human patients (1999) (0)
- Re: allogenic transplantation after nonmyelosuppressive conditioning--the effect of single-agent pentostatin. (2004) (0)
- Advance care planning in metastatic cancer patients: A quality improvement initiative. (2021) (0)
- 780: Carbonic Anhydrase IX (CAIX) Expression and VHL Gene Alteration as Predictors of Survival in Renal Cell Carcinoma (2004) (0)
- Predicting real-world effectiveness using overall survival and progression-free survival-based clinical trial efficacy measures. (2016) (0)
- 47 Prognostic significance of microvascular invasion in renal clear cell carcinoma (2005) (0)
- Decline in serum soluble E-cadherin and low baseline matrix metalloproteinase-9 are associated with response to combination celecoxib and erlotinib therapy in advanced non-small cell lung cancer (2007) (0)
- Continue NCCN Clinical Practice Guidelines in Oncology TM Non-Small Cell Lung Cancer (0)
- Pilot study of VHL mutation analysis to predict response to interleukin-2 in patients with metastatic renal cell carcinoma. (2006) (0)
- P53 is an independent predictor of tumor recurrence and progression after nephrectomy for patients with localized Renal Cell Carcinoma: Implications for surveillance and adjuvant clinical trials. (2004) (0)
- Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium. (2018) (0)
- Adjuvant H igh-Dose B olus I nterleukin-2 f or P atients W ith High-Risk R enal C ell C arcinoma: A C ytokine W orking G roup Randomized T rial (2003) (0)
- Contents Vol. 78, 2010 (2010) (0)
- ASCO 21 - Recommended Abstracts in Kidney Cancer (2021) (0)
- Chapter 14 – Treatment of Advanced Renal Cell Carcinoma (2005) (0)
- Faculty Opinions recommendation of Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (2006) (0)
- 449 CAIX LEVEL AND VHL MUTATION DO NOT IMPROVE THE ABILITY TO PREDICT RENAL CELL CARCINOMA-SPECIFIC MORTALITY IN PATIENTS TREATED WITH NEPHRECTOMY (2007) (0)
- Biosensors to assess performance status in cancer (BioAPS Study). (2016) (0)
- MP35-17 COMBINATION OF MTOR INHIBITION AND CD4 DEPLETION GENERATES ANTITUMOR IMMUNITY (2014) (0)
- Expansion of an advance care planning initiative in patients with metastatic cancer: Successes and challenges. (2022) (0)
- MP-19.13 (2006) (0)
- WITHDRAWN: Renal cell carcinoma: An update for the practicing urologist (2014) (0)
- 349: Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3) is Preferentially Expressed in Papillary Renal Cell Carcinoma (RCC). (2005) (0)
- Subject Index Vol. 78, 2010 (2010) (0)
- RE: QUANTITATIVE POLYMERASE CHAIN REACTION DOES NOT IMPROVE PREOPERATIVE PROSTATE CANCER STAGING (1998) (0)
- The Evolving Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma (2016) (0)
- The Role of Combination Biologic Therapy in the Immunotherapeutic Approach to the Treatment of Renal Cell Carcinoma (1992) (0)
- Long-term survival following nephrectomy for renal cell carcinoma: The 15 year University of California-Los Angeles experience. (2006) (0)
- Abstract 5604: Modulation of Stat3 in the tumor microenvironment enhances adoptive T cell therapy (2010) (0)
- Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma (2004) (0)
- Successful biosimilar adoption in oncology: strategic approach to system standardization. (2022) (0)
- Elevated pS6K levels in the sarcomatoid component of tumors derived from patients with metastatic renal cell carcinoma (mRCC). (2013) (0)
- The Use of Cytokines, Tumor Infiltrating Lymphocytes, and Gene Therapy in the Treatment of Advanced Renal Cell Carcinoma: The UCLA Experience (1995) (0)
- PD2-4 Survival Advantage of Temsirolimus Validates a Role for Mammalian Target of Rapamycin (mTOR) in the Biology of Advanced Renal Cell Carcinoma (2008) (0)
- Biological response modifiers in metastatic renal cell carcinoma (1992) (0)
- Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC). (2014) (0)
- Adoptive Immunotherapy in Renal Cell Carcinoma (2000) (0)
- Serum biomarkers predict response to combination celecoxib and erlotinib therapy in advanced non-small cell lung cancer: P3-033 (2007) (0)
- Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases. (2017) (0)
- Antiangiogenic Therapies in Renal Cell Carcinoma (2008) (0)
- Renal Cell Carcinoma: Recent Progress and Future Directions1 (2019) (0)
- Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary. (2018) (0)
- Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Response (2011) (0)
- Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib. (2014) (0)
- FOR HIGHER SPECIFIC KILLING BY TNF-SECRETORS IN VITRO (1993) (0)
- Fluorouracil does not enhance the limited effectiveness of subcutaneous recombinant interleukin-2 and recombinant interferon alfa-2a for metastatic renal cancer (2001) (0)
- Clinical researchRenal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection1 (2004) (0)
- Renal Cancer Vaccines (2004) (0)
- 497 The use of UISS (UCLA integrated staging system) to predict survival in renal cell carcinoma: An international multicentre study in 4202 patients (2004) (0)
- S-TRAC trial: Sensitivity analyses of disease-free survival (DFS). (2018) (0)
- Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification. (2021) (0)
- 1103: Long-Term Survival Following Nephrectomy for Renal Cell Carcinoma: The 15 Year UCLA Experience (2006) (0)
- 1611P Health-related quality of life, vaccine uptake and immune response among cancer patients undergoing treatment during the COVID-19 pandemic (2021) (0)
- 1337: Endothelial Expression of Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3), but not VEGFR-1 or VEGFR-2, Predicts Survival in Clear Cell Renal Cell Carcinoma (RCC) (2005) (0)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. (2023) (0)
- Biotherapy with interferon in solid tumors. (1987) (0)
- Expression of CXC Chemokines during IL-2 Therapy Correlates with Response in Metastatic Renal Cell Carcinoma (2004) (0)
- Development and Incorporation of Biomarkers in RCC Therapeutics (2015) (0)
- Book Review Clinical Management of Renal Tumors Edited by Ronald M. Bukowski and Andrew C. Novick. 663 pp., illustrated. Totowa, NJ, Humana Press, 2008. $149. 978-1-58829-251-3 (2008) (0)
- Rigaud and Schmincke Types of Lymphoepithelioma (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert Alan Figlin?
Robert Alan Figlin is affiliated with the following schools:
